Yatiri Bio
San Diego, US · Founded 2021 · Delaware corporation
Find your way into Yatiri Bio
172 people in our graph share verified history with the Yatiri Bio team — schools, employers, funds. One of them is your warm intro.
Neha Jewalikarunlockedknows Pilgrim Jackson · together at University of California, Santa Cruz
×11knows the team · via University of California, Santa Cruz
Yatiri Bio applies unbiased proteomics, deep learning, and patient-derived cellular models to cancer drug discovery, building a molecularly defined patient landscape to identify ideal patient subsets for novel therapeutics. It offers computational tools such as its ProteoBrowser data portal and ProteoModels cellular systems for oncology drug developers working on personalized medicine.
Founders & leadership
Yatiri Bio was founded in 2021 by Pilgrim Jackson.
PJ
Pilgrim JacksoninCEO/FounderPilgrim Jackson previously led proteomics and protein sciences teams at Celgene, where he integrated computational and experimental approaches to advance drug discovery in inflammation and oncology, delivering six therapeutics to clinical development and generating four patents. He is co-founder and CEO of Yatiri Bio, which applies proteomics, machine learning, and patient-derived cellular models to advance cancer drug discovery and personalized medicine.
TK
toni kollerinFounder
RA
Raman AfsharinNamed on SEC filing
MA
Mahan AbbasianinChief Operating Officer & Co-Founder
AM
Afshin MahmoudiinVice President Of Business Development
Reported raises · per SEC filings
Form D private placements$2.9M disclosed across 2 rounds · 2021–2022
▶$1.2MraisedMar 2024 · 13 investors · Other TechnologyRule 506(b)
▶$1.2MraisedMar 2024 · 13 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Mahan AbbasianExecutive Officer, Director
- Afshin MahmoudiExecutive Officer, Director
- Raman AfsharExecutive Officer, Director
- Pilgrim JacksonExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $1.2M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.7MraisedJul 2021 · 21 investors · Other TechnologyRule 506(b)
▶$1.7MraisedJul 2021 · 21 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Pilgrim JacksonExecutive Officer, Director
- Raman AfsharDirector
- Mahan AbbasianDirector
- Afshin MahmoudiDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
IRIS MEDICINE3 shared keywordsIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.
Epirium3 shared keywordsEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
Araris Biotech3 shared keywordsAraris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
MOBILion Systems, Inc.3 shared keywordsMOBILion Systems develops the MOBIE platform, a high-resolution ion mobility mass spectrometry (HRIM-MS) instrument that separates and identifies complex molecules in separation science. It serves pharmaceutical, biopharma, academic, and diagnostics labs across cell and gene therapy, therapeutic characterization, food and environmental testing, and biomarker research.
Companies competing with Yatiri Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Yatiri Bio do?
- Yatiri Bio applies unbiased proteomics, deep learning, and patient-derived cellular models to cancer drug discovery, building a molecularly defined patient landscape to identify ideal patient subsets for novel therapeutics. It offers computational tools such as its ProteoBrowser data portal and ProteoModels cellular systems for oncology drug developers working on personalized medicine.
- Who founded Yatiri Bio?
- Yatiri Bio was founded by Pilgrim Jackson in 2021.
- How much funding has Yatiri Bio raised?
- Yatiri Bio has disclosed $2.9M raised across 2 rounds.
- Where is Yatiri Bio headquartered?
- Yatiri Bio is headquartered in San Diego, US.